Public health experts and presidentail staffers express frustration over coronavirus disease 2019 (COVID-19) testing comments made by President Trump; the NIH has halted a clinical trial of hydroxychloroquine after data show no harm or benefit in patients with COVID-19; individuals who have obsessive-compulsive disorder may be at greater risk due to added stress from the pandemic.
Public health experts and staffers from the Trump administration both expressed frustration over comments the President made during a campaign rally on Saturday, in which he said he asked officials to slow down testing for coronavirus disease 2019 (COVID-19). Reported by The Washington Post, experts stress that a crucial part of controlling the pandemic involves increased testing, especially as the virus continues to impact states and is poised to surge in the fall similar to the seasonal flu. Meanwhile, several states that have begun the process of reopening have also seen their daily case totals go up.
On Saturday, the NIH issued a news release stating that it had halted a clinical trial examining the safety and effectiveness of hydroxychloroquine as a COVID-19 treatment, with study data indicating that although the treatment does no harm, it also provides no benefit. Touted by the Trump administration, malaria drug hydroxychloroquine was evaluated by a data and safety monitoring board (DSMB). Following its fourth interim analysis, the DSMB recommended that the National Heart, Lung, and Blood Institute, part of the NIH, stop the trial, which it did immediately.
A piece by Kaiser Health News spotlighted how patients with obsessive-compulsive disorder (OCD) are dealing with additional anxiety precipitated by the pandemic. Nearly 7 in 10 employees indicated in a poll that the pandemic is the most stressful time of their professional career, and at-risk populations, such as those with OCD, may be more inclined to repeat certain behaviors or they may fixate on nonstop intrusive thoughts. However, those who have undergone successful treatment for OCD may be better equipped to accept the pandemic’s uncertainty because their interventions have focused on protecting against the stress of everyday life and the virus.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More